- Home
- CGNT vs KROS Comparison
CGNT vs KROS Comparison
Compare CGNT & KROS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CGNT
- KROS
- Stock Information
- Founded
- CGNT 2020
- KROS 2015
- Country
- CGNT Israel
- KROS United States
- Employees
- CGNT N/A
- KROS N/A
- Industry
- CGNT Computer Software: Prepackaged Software
- KROS Biotechnology: Pharmaceutical Preparations
- Sector
- CGNT Technology
- KROS Health Care
- Exchange
- CGNT Nasdaq
- KROS Nasdaq
- Market Cap
- CGNT 617.3M
- KROS 565.0M
- IPO Year
- CGNT N/A
- KROS 2020
- Fundamental
- Price
- CGNT $8.28
- KROS $15.03
- Analyst Decision
- CGNT Buy
- KROS Buy
- Analyst Count
- CGNT 2
- KROS 14
- Target Price
- CGNT $14.00
- KROS $20.56
- AVG Volume (30 Days)
- CGNT 260.3K
- KROS 978.0K
- Earning Date
- CGNT 12-10-2025
- KROS 11-06-2025
- Dividend Yield
- CGNT N/A
- KROS N/A
- EPS Growth
- CGNT N/A
- KROS N/A
- EPS
- CGNT N/A
- KROS 0.47
- Revenue
- CGNT $376,566,000.00
- KROS $232,844,000.00
- Revenue This Year
- CGNT $15.30
- KROS $6,657.47
- Revenue Next Year
- CGNT $11.30
- KROS N/A
- P/E Ratio
- CGNT N/A
- KROS $31.97
- Revenue Growth
- CGNT 14.04
- KROS 85820.30
- 52 Week Low
- CGNT $6.38
- KROS $9.12
- 52 Week High
- CGNT $11.66
- KROS $72.37
- Technical
- Relative Strength Index (RSI)
- CGNT 49.17
- KROS 48.77
- Support Level
- CGNT $7.82
- KROS $13.60
- Resistance Level
- CGNT $8.28
- KROS $15.76
- Average True Range (ATR)
- CGNT 0.26
- KROS 0.74
- MACD
- CGNT 0.02
- KROS -0.03
- Stochastic Oscillator
- CGNT 56.63
- KROS 53.87
About CGNT Cognyte Software Ltd.
Cognyte Software Ltd provides security analytics software that empowers governments and enterprises with Actionable Intelligence. Its interface software is designed to help customers accelerate and improve the effectiveness of investigations and decision-making.
About KROS Keros Therapeutics Inc.
Keros Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from hematological, pulmonary, and cardiovascular disorders with high unmet medical needs. The company's protein therapeutic product candidate, KER-050, is being developed for the treatment of low blood cells counts, or cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndromes, or MDS, and in patients with myelofibrosis.